Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.30 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | TOP2A | P11388 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9288133 | 0.79 | — | — | |
| SCHEMBL2896436 | 0.77 | — | — | |
| SCHEMBL873728 | 0.70 | CYP2E1 (0.49) | NOS2CYP2E1CYP2C8CYP2D6CYP2A6 | |
| SCHEMBL24250240 | 0.70 | SLC6A2 (0.41) | NOS2NOS3NOS1CYP2A6 | |
| SCHEMBL13654965 | 0.70 | — | — | |
| SCHEMBL17772009 | 0.70 | CYP2E1 (0.45) | NOS2NOS1CYP2E1CYP2C8CYP2D6 | |
| SCHEMBL19413769 | 0.70 | UHRF1 (0.45) | NOS2NOS3NOS1CYP2A6 | |
| SCHEMBL21983980 | 0.69 | — | — | |
| SCHEMBL13844519 | 0.68 | GABRA1 (0.37) | NOS2NOS3NOS1 | |
| SCHEMBL13028890 | 0.68 | NUDT1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286390-A1 | PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS | NISSAN CHEMICAL INDUSTRIES LIMITED | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286390-A1 | PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS | P2RY1, P2RX7, P2RX1 | NOS2 2029/4885NOS3 2133/4885NOS1 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.